BusinessInvivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 MutationsBy Nasdaq OMXMay 8, 2018, 10:01 AM UTC
BusinessInvivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay KitBy Nasdaq OMXAug 1, 2017, 10:00 AM UTC
